Table 1 Baseline comparisons between KRAS wildtype and KRAS mutant patients.

From: Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients

 

KRAS wildtype (n = 345)

KRAS mutant (n = 141)

p value†

N

%

n

%

Cohort

    

< 0.001

 TRIBE arm A

96

28

93

66

 

 FIRE3 Bev arm

249

72

48

34

 

Gender

    

0.39

 Male

220

64

84

60

 

 Female

125

36

57

40

 

Age (years)

     

 Median (range)

63 (29–76)

62 (33–75)

   

 ≤ 65

189

55

83

59

0.41

 > 65

156

45

58

41

 

Performance status

    

0.004

 ECOG 0

212

61

106

75

 

 ECOG ≥ 1

133

39

35

25

 

Primary tumor site

    

0.75

 Right-sided colon

84

25

23

27

 

 Left-sided colon

251

75

63

72

 

 Unknown*

10

 

55

  

Primary tumor resected

    

0.099

 Yes

280

81

105

74

 

 No

65

19

36

26

 

Adjuvant chemotherapy

    

0.39

 Yes

60

17

20

14

 

 No

285

83

121

86

 
  1. †p value was based on Chi-square test.
  2. *Unknown group was not included in the analysis.
Back to article page